Gano Kyle, CEO of Neurocrine Biosciences ($NBIX), sold about $4.9 million in company shares across three open market transactions over the past year. His most recent sale occurred on January 16, 2026. These sales rank him 1,975th among 11,678 insiders by total value sold, below the average of $8.6 million per insider and 6 transactions. Gano Kyle made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 12, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Restricted Stock Unit | 4907 | $0.00 | 14,721.0000 | 102,500,000 | 25.00% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Restricted Stock Unit | 2566 | $0.00 | 2,566.0000 | 102,500,000 | 50.00% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Restricted Stock Unit | 2241 | $0.00 | 4,484.0000 | 102,500,000 | 33.32% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | F | Common Stock | 5378 | $124.12 | 150,815.0000 | 102,500,000 | 3.44% | 0.01% |
| Feb. 12, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 4907 | $0.00 | 146,661.0000 | 102,500,000 | 3.46% | 0.00% |
| Feb. 12, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | F | Common Stock | 2648 | $123.10 | 144,013.0000 | 102,500,000 | 1.81% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 2241 | $0.00 | 146,254.0000 | 102,500,000 | 1.56% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | F | Common Stock | 1210 | $124.12 | 145,044.0000 | 102,500,000 | 0.83% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 2566 | $0.00 | 147,610.0000 | 102,500,000 | 1.77% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | F | Common Stock | 1385 | $124.12 | 146,225.0000 | 102,500,000 | 0.94% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | A | Common Stock | 9968 | $0.00 | 156,193.0000 | 102,500,000 | 6.82% | 0.01% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | A | Restricted Stock Unit | 20142 | $0.00 | 20,142.0000 | 102,500,000 | 9999.99% | 0.02% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | A | Stock Option | 114830 | $0.00 | 114,830.0000 | 102,500,000 | 9999.99% | 0.11% |
| Jan. 31, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 2927 | $0.00 | 143,334.0000 | 102,500,000 | 2.08% | 0.00% |
| Jan. 31, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | F | Common Stock | 1580 | $136.06 | 141,754.0000 | 102,500,000 | 1.10% | 0.00% |
| Jan. 31, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Restricted Stock Unit | 2927 | $0.00 | 0.0000 | 102,500,000 | 100.00% | 0.00% |
| Jan. 16, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 34588 | $35.99 | 174,995.0000 | 102,500,000 | 24.63% | 0.03% |
| Jan. 16, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Incentive Stock Option | 1812 | $0.00 | 0.0000 | 102,500,000 | 100.00% | 0.00% |
| Jan. 16, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Non-Qualified Stock Option | 34588 | $0.00 | 0.0000 | 102,500,000 | 100.00% | 0.03% |
| Jan. 16, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | S | Common Stock | 1812 | $132.71 | 140,407.0000 | 102,500,000 | 1.27% | 0.00% |
| Jan. 16, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 1812 | $35.99 | 142,219.0000 | 102,500,000 | 1.29% | 0.00% |
| Jan. 16, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | S | Common Stock | 34588 | $132.70 | 140,407.0000 | 102,500,000 | 19.77% | 0.03% |
| Nov. 1, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Restricted Stock Unit | 613 | $0.00 | 1,842.0000 | 102,500,000 | 24.97% | 0.00% |
| Nov. 4, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | S | Common Stock | 300 | $141.97 | 140,407.0000 | 102,500,000 | 0.21% | 0.00% |
| Nov. 1, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 613 | $0.00 | 140,720.0000 | 102,500,000 | 0.44% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 2241 | $0.00 | 141,113.0000 | 103,700,000 | 1.61% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | S | Common Stock | 1352 | $116.84 | 138,872.0000 | 103,700,000 | 0.96% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 2566 | $0.00 | 140,224.0000 | 103,700,000 | 1.86% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Restricted Stock Unit | 2241 | $0.00 | 6,725.0000 | 103,700,000 | 24.99% | 0.00% |
| Feb. 12, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | A | Restricted Stock Unit | 19628 | $0.00 | 19,628.0000 | 103,700,000 | 9999.99% | 0.02% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Restricted Stock Unit | 2566 | $0.00 | 5,132.0000 | 103,700,000 | 33.33% | 0.00% |
| Feb. 12, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | A | Stock Option | 104736 | $0.00 | 104,736.0000 | 103,700,000 | 9999.99% | 0.10% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | S | Common Stock | 1206 | $116.86 | 139,907.0000 | 103,700,000 | 0.85% | 0.00% |
| Feb. 8, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 1860 | $0.00 | 138,638.0000 | 103,700,000 | 1.36% | 0.00% |
| Feb. 10, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | S | Common Stock | 980 | $118.39 | 137,658.0000 | 103,700,000 | 0.71% | 0.00% |
| Feb. 8, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Restricted Stock Unit | 1860 | $0.00 | 0.0000 | 103,700,000 | 100.00% | 0.00% |
| Jan. 31, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Restricted Stock Unit | 2927 | $0.00 | 2,927.0000 | 103,700,000 | 50.00% | 0.00% |
| Jan. 31, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 2927 | $0.00 | 138,319.0000 | 103,700,000 | 2.16% | 0.00% |
| Jan. 31, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | S | Common Stock | 1541 | $152.87 | 136,778.0000 | 103,700,000 | 1.11% | 0.00% |
| Jan. 15, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 60188 | $32.99 | 195,580.0000 | 103,700,000 | 44.45% | 0.06% |
| Jan. 15, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | S | Common Stock | 60188 | $141.50 | 135,392.0000 | 103,700,000 | 30.77% | 0.06% |
| Jan. 15, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Non-Qualified Stock Option | 60188 | $0.00 | 0.0000 | 103,700,000 | 100.00% | 0.06% |
| Jan. 15, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Incentive Stock Option | 4812 | $0.00 | 0.0000 | 103,700,000 | 100.00% | 0.00% |
| Jan. 15, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | M | Common Stock | 4812 | $32.99 | 140,204.0000 | 103,700,000 | 3.55% | 0.00% |
| Jan. 15, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | S | Common Stock | 4812 | $141.50 | 135,392.0000 | 103,700,000 | 3.43% | 0.00% |
| Nov. 1, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | A | Restricted Stock Unit | 2455 | $0.00 | 2,455.0000 | 104,300,000 | 9999.99% | 0.00% |
| Nov. 1, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Executive Officer | A | Stock Option | 13344 | $0.00 | 13,344.0000 | 104,300,000 | 9999.99% | 0.01% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | A | Stock Option | 45058 | $0.00 | 45,058.0000 | 101,000,000 | 9999.99% | 0.04% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | S | Common Stock | 1352 | $132.89 | 135,166.0000 | 101,000,000 | 0.99% | 0.00% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | A | Restricted Stock Unit | 8966 | $0.00 | 8,966.0000 | 101,000,000 | 9999.99% | 0.01% |
| Feb. 8, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | S | Common Stock | 980 | $134.20 | 133,952.0000 | 101,000,000 | 0.73% | 0.00% |
| Feb. 6, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | S | Common Stock | 1600 | $142.20 | 133,072.0000 | 101,000,000 | 1.19% | 0.00% |
| Jan. 31, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | S | Common Stock | 1541 | $140.70 | 131,635.0000 | 101,000,000 | 1.16% | 0.00% |
| Jan. 2, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | M | Common Stock | 68884 | $19.59 | 199,134.0000 | 101,000,000 | 52.89% | 0.07% |
| Jan. 2, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | M | Incentive Stock Option | 6116 | $19.59 | 0.0000 | 101,000,000 | 100.00% | 0.01% |
| Jan. 2, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | M | Common Stock | 6116 | $19.59 | 136,366.0000 | 101,000,000 | 4.70% | 0.01% |
| Jan. 2, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | S | Common Stock | 6116 | $131.44 | 130,250.0000 | 101,000,000 | 4.48% | 0.01% |
| Jan. 2, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | M | Non-Qualified Stock Option | 68884 | $19.59 | 0.0000 | 101,000,000 | 100.00% | 0.07% |
| Jan. 2, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | S | Common Stock | 68884 | $131.47 | 130,250.0000 | 101,000,000 | 34.59% | 0.07% |
| Aug. 21, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | S | Common Stock | 2132 | $107.41 | 130,250.0000 | 98,900,000 | 1.61% | 0.00% |
| Feb. 13, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | A | Restricted Stock Unit | 10264 | $0.00 | 10,264.0000 | 98,900,000 | 9999.99% | 0.01% |
| Feb. 13, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | A | Stock Option | 63789 | $0.00 | 63,789.0000 | 98,900,000 | 9999.99% | 0.06% |
| Feb. 7, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | S | Common Stock | 1623 | $102.29 | 115,719.0000 | 98,900,000 | 1.38% | 0.00% |
| Feb. 8, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | S | Common Stock | 980 | $103.99 | 128,096.0000 | 98,900,000 | 0.76% | 0.00% |
| Feb. 6, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | S | Common Stock | 1600 | $105.64 | 114,257.0000 | 98,900,000 | 1.38% | 0.00% |
| Feb. 7, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | S | Common Stock | 12801 | $102.41 | 127,216.0000 | 98,900,000 | 9.14% | 0.01% |
| Jan. 31, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | Gano Kyle | Chief Business Development Off | S | Common Stock | 1541 | $109.98 | 112,820.0000 | 98,900,000 | 1.35% | 0.00% |